Program on proposed endovascular treatment of chronic cerebrospinal venous insufficiency

July 21st, 2010
The Departments of Radiology and Neurology at SUNY Downstate Medical Center will hold a symposium on CCSVI (chronic cerebrospinal venous insufficiency) on Monday, July 26 from 9:00 am to 4:00 pm, in the Alumni Auditorium, 395 Lenox Road, Brooklyn, New York 11203.

CCSVI is a syndrome in which blood flow from the brain is compromised. While CCSVI is a disease state that by itself often requires intervention, it has been proposed that the syndrome promotes the development of multiple sclerosis (MS). Speakers from the United States, Bulgaria, Italy, and Kuwait will present a thorough review of CCSVI, including the proposed relationship between CCSVI and MS.

Salvatore J. A. Sclafani, MD, professor and chair of radiology at SUNY Downstate, has organized the symposium and will provide an overview of CCSVI for interventional radiologists.

While this free symposium is directed at physicians and other healthcare providers, members of the general public are invited and there will be a presentation on patient activism. Those wishing to attend should respond in advance to CCSVISymposium@gmail.com.

Provided by SUNY Downstate Medical Center

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...